Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Net Income: 2009-2025

Historic Net Income for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to $2.0 million.

  • Aytu Biopharma's Net Income rose 415.75% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 195.99%. This contributed to the annual value of $620,000 for FY2025, which is 118.65% up from last year.
  • Latest data reveals that Aytu Biopharma reported Net Income of $2.0 million as of Q3 2025, which was up 3,069.35% from $62,000 recorded in Q2 2025.
  • Over the past 5 years, Aytu Biopharma's Net Income peaked at $2.0 million during Q3 2025, and registered a low of -$53.3 million during Q1 2022.
  • For the 3-year period, Aytu Biopharma's Net Income averaged around -$956,545, with its median value being -$599,000 (2024).
  • As far as peak fluctuations go, Aytu Biopharma's Net Income slumped by 546.80% in 2021, and later surged by 415.75% in 2025.
  • Quarterly analysis of 5 years shows Aytu Biopharma's Net Income stood at -$11.5 million in 2021, then surged by 42.04% to -$6.7 million in 2022, then surged by 87.46% to -$839,000 in 2023, then soared by 114.66% to $123,000 in 2024, then spiked by 415.75% to $2.0 million in 2025.
  • Its Net Income was $2.0 million in Q3 2025, compared to $62,000 in Q2 2025 and $54,000 in Q1 2025.